コンテンツへスキップ
Merck
  • Uremic metabolites impair skeletal muscle mitochondrial energetics through disruption of the electron transport system and matrix dehydrogenase activity.

Uremic metabolites impair skeletal muscle mitochondrial energetics through disruption of the electron transport system and matrix dehydrogenase activity.

American journal of physiology. Cell physiology (2019-07-11)
Trace Thome, Zachary R Salyers, Ravi A Kumar, Dongwoo Hahn, Fabian N Berru, Leonardo F Ferreira, Salvatore T Scali, Terence E Ryan
要旨

Chronic kidney disease (CKD) leads to increased skeletal muscle fatigue, weakness, and atrophy. Previous work has implicated mitochondria within the skeletal muscle as a mediator of muscle dysfunction in CKD; however, the mechanisms underlying mitochondrial dysfunction in CKD are not entirely known. The purpose of this study was to define the impact of uremic metabolites on mitochondrial energetics. Skeletal muscle mitochondria were isolated from C57BL/6N mice and exposed to vehicle (DMSO) or varying concentrations of uremic metabolites: indoxyl sulfate, indole-3-acetic-acid, l-kynurenine, and kynurenic acid. A comprehensive mitochondrial phenotyping platform that included assessments of mitochondrial oxidative phosphorylation (OXPHOS) conductance and respiratory capacity, hydrogen peroxide production (JH2O2), matrix dehydrogenase activity, electron transport system enzyme activity, and ATP synthase activity was employed. Uremic metabolite exposure resulted in a ~25-40% decrease in OXPHOS conductance across multiple substrate conditions (P < 0.05, n = 5-6/condition), as well as decreased ADP-stimulated and uncoupled respiratory capacity. ATP synthase activity was not impacted by uremic metabolites; however, a screen of matrix dehydrogenases indicated that malate and glutamate dehydrogenases were impaired by some, but not all, uremic metabolites. Assessments of electron transport system enzymes indicated that uremic metabolites significantly impair complex III and IV. Uremic metabolites resulted in increased JH2O2 under glutamate/malate, pyruvate/malate, and succinate conditions across multiple levels of energy demand (all P < 0.05, n = 4/group). Disruption of mitochondrial OXPHOS was confirmed by decreased respiratory capacity and elevated superoxide production in cultured myotubes. These findings provide direct evidence that uremic metabolites negatively impact skeletal muscle mitochondrial energetics, resulting in decreased energy transfer, impaired complex III and IV enzyme activity, and elevated oxidant production.

材料
製品番号
ブランド
製品内容

Sigma-Aldrich
ウシ血清アルブミン ウシ血清由来, heat shock fraction, protease free, fatty acid free, essentially globulin free, pH 7, ≥98%
Sigma-Aldrich
リン酸カリウム 二塩基性, ACS reagent, ≥98%
Sigma-Aldrich
HEPES, ≥99.5% (titration)
Sigma-Aldrich
ジメチルスルホキシド, anhydrous, ≥99.9%
Sigma-Aldrich
水素化ホウ素ナトリウム, powder, ≥98.0%
Sigma-Aldrich
塩化カリウム, for molecular biology, ≥99.0%
Sigma-Aldrich
Triton X-100, laboratory grade
Sigma-Aldrich
ペルオキシダーゼ from horseradish, Type VI, essentially salt-free, lyophilized powder, ≥250 units/mg solid (using pyrogallol)
Sigma-Aldrich
アンチマイシンA 放線菌由来
Sigma-Aldrich
n-ドデシル β-D-マルトシド, ≥98% (GC)
Sigma-Aldrich
オリゴマイシンA, ≥99% (HPLC)
Sigma-Aldrich
ホウ酸, BioReagent, for molecular biology, suitable for cell culture, suitable for plant cell culture, ≥99.5%
Sigma-Aldrich
カルボニルシアニド 4-(トリフルオロメトキシ)フェニルヒドラゾン, ≥98% (TLC), powder
Sigma-Aldrich
ロテノン, ≥95%
Sigma-Aldrich
シトクロムC from equine heart, ≥95% (SDS-PAGE)
Sigma-Aldrich
β-ニコチンアミドアデニンジヌクレオチド ナトリウム塩 from Saccharomyces cerevisiae
Sigma-Aldrich
2,6-ジクロロインドフェノール ナトリウム塩 水和物, suitable for vitamin C determination, BioReagent
Sigma-Aldrich
キヌレン酸, ≥98%
Sigma-Aldrich
コエンザイムA 三リチウム塩, ≥93%
Sigma-Aldrich
L-キヌレニン, ≥98% (HPLC)
Sigma-Aldrich
シアン化カリウム, BioUltra, ≥98.0% (AT)
Roche
ホスホエノールピルビン酸, 97% (PEP-K), pkg of 1 g
Sigma-Aldrich
セルリティック M, Cell Lysis Reagent, Suitable for Mammalian cell lysis and protein solubilization.